Newborn baby shows liver damage after first dose of Remdesivir: The Tribune India


Tribune press service

Naina Mishra

Chandigarh, May 20

IGP researchers have reported a bizarre case of a 14-day-old Covid-19 positive child showing liver damage after being injected with Remdesivir, a drug widely used in Covid-19 patients during the second wave . The research paper expressed alarm against the use of Remdesivir in less severe patients.

Doctors at the Center for Advanced Pediatrics, PGI, presented the case of a newborn in an article titled, “Remdesivir-induced liver injury in a Covid-positive newborn,” published in the Indian Journal of Paediatrics.

According to the newspaper, a newborn with Covid-19, who suffered from severe hypoxemia (low oxygen levels) requiring intubation, was admitted to the IGP. When remdesivir was given, the baby experienced worsening transaminitis (liver inflammation) requiring drug discontinuation, after which liver enzymes normalized over the next two weeks.

The 14-day-old breastfed baby developed poor feeding, lethargy and rapid breathing on day 13 of his life. The baby was in respiratory distress requiring continuous positive airway pressure (CPAP). The chest X-ray suggested viral pneumonia and the baby tested positive for Covid. The baby had worsening distress and was intubated on day 5 of the hospital stay.

Given the possibility of severe Covid pneumonia, the baby was injected with Remdesivir. After starting Remdesivir, the baby had severe inflammation of the liver after his first dose.

The researchers say drug-induced liver damage versus Covid infection-induced hepatitis was considered and Remdesivir was stopped after the first dose.

The researchers said the child’s liver enzymes gradually normalized on day 15 of the hospital stay and the baby was discharged on day 18 while breastfeeding.

Since derangement and improvement in liver function tests had a temporal association with starting and stopping Remdesivir treatment, respectively, drug-induced liver injury was considered more likely, the doctors said. .

“Remdesivir has shown a decrease in length of hospitalization and a modest survival benefit in moderate and severe Covid infections in adult patients. Remdesivir can increase transaminases and has been avoided in patients with pre-existing hepatic impairment. Remdesivir should be used with caution and limited only to cases of severe Covid infection,” the article read.

The research paper reads

“Remdesivir has shown a decrease in length of hospitalization and a modest survival benefit in moderate and severe Covid infections in adult patients. Remdesivir can increase transaminases and has been avoided in patients with pre-existing hepatic impairment. Remdesivir should be used with caution and limited only to cases of severe Covid infection,” the article read.

Comments are closed.